Press release
March 26, 2026
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
LeonaBio, Inc. (LONA)
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received Gross Proceeds of $90 Million in Private Placement Financing